Antares Patent-Cliff Exposure & CMS Drug Spending Portfolio

Antares (US): 3 reconciled FDA prescription therapies (0.6% 2025 to 2030 cliff risk), $41.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.6%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$41.5M
2024 Medicare Part D Spend$29.1M
2024 Medicaid Spend$12.4M
California HCAI SB 17 Filings3 WAC filings (max 15.8% 2-yr change)